BLPH Bellerophon Therapeutics, Inc.

1.39
+0  (35%)
Previous Close 1.03
Open 1.25
Price To book 0.83
Market Cap 20.16M
Shares 14,506,000
Volume 7,922,795
Short Ratio 1.20
Av. Daily Volume 1,605,570

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated May 2016. Data due mid-2017.
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 3 commenced enrollment June 2016. Interim analysis due 4Q 2017 with top-line data due mid-2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2 initiated 3Q 2016. Data due mid-2017.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)

Latest News

  1. The Difference Between Spectacular News and No News
  2. BELLEROPHON THERAPEUTICS, INC. Financials
  3. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
  4. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
  5. Bellerophon Therapeutics posts 4Q loss
  6. Bellerophon Therapeutics posts 4Q loss
  7. Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
  8. BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
  9. LifeSci Capital Initiates Coverage of Bellerophon Therapeutics
  10. Coverage initiated on Bellerophon Therapeutics by H.C. Wainwright
  11. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
  12. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  13. Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program
  14. Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program
  15. These 5 Stocks Under $10 Could Make You a Lot of Money
  16. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  17. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a
  18. Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering
  19. BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or
  20. Bellerophon Reports Third Quarter 2016 Financial Results and Provides Business Update